Study summary
A newer intensive regimen, BrECADD, was both gentler and more effective than eBEACOPP
94.3% vs 90.9%free of progression at 4 years, BrECADD vs eBEACOPP
What was tested
BrECADD, a regimen that includes brentuximab vedotin, against eBEACOPP, a strong standard regimen in Europe, for adults up to 60 with advanced Hodgkin lymphoma. Cycles were adjusted by PET scan.
What they found
- Treatment-related health problems occurred in 42% on BrECADD and 59% on eBEACOPP.
- At 4 years, 94.3% on BrECADD and 90.9% on eBEACOPP had no progression.
- Overall survival was about 98% in both groups.
- A later analysis found fertility recovered better after BrECADD.
What it means
Became a standard choice in Europe. In the US, nivolumab-AVD is the newly approved option.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.